BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Inhibition of p90RSK activation sensitizes triple-negative breast cancer cells to cisplatin by inhibiting proliferation, migration and EMT

  • Jin, Yujin (College of Pharmacy and Institute of Drug Research and Development, Chungnam National University) ;
  • Huynh, Diem Thi Ngoc (College of Pharmacy and Institute of Drug Research and Development, Chungnam National University) ;
  • Kang, Keon Wook (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Myung, Chang-Seon (College of Pharmacy and Institute of Drug Research and Development, Chungnam National University) ;
  • Heo, Kyung-Sun (College of Pharmacy and Institute of Drug Research and Development, Chungnam National University)
  • Received : 2019.09.26
  • Accepted : 2019.11.14
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Cisplatin (Cis-DDP) is one of the most widely used anti-cancer drugs. It is applicable to many types of cancer, including lung, bladder, and breast cancer. However, its use is now limited because of drug resistance. p90 ribosomal S6 kinase (p90RSK) is one of the downstream effectors in the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) pathway and high expression of p90RSK is observed in human breast cancer tissues. Therefore, we investigated the role of p90RSK in the Cis-DDP resistance-related signaling pathway and epithelial-mesenchymal transition (EMT) in breast cancer cells. First, we discovered that MDA-MB-231 cells exhibited more Cis-DDP resistance than other breast cancer cells, including MCF-7 and BT549 cells. Cis-DDP increased p90RSK activation, whereas the inactivation of p90RSK using a small interfering RNA (siRNA) or dominant-negative kinase mutant plasmid overexpression significantly reduced Cis-DDP-induced cell proliferation and migration via the inhibition of matrix metallopeptidase (MMP)2 and MMP9 in MDA-MB-231 cells. In addition, p90RSK activation was involved in EMT via the upregulation of mRNA expression, including that of Snail, Twist, ZEB1, N-cadherin, and vimentin. We also investigated NF-κB, the upstream regulator of EMT markers, and discovered that Cis-DDP treatment led to NF-κB translocation in the nucleus as well as its promoter activity. Our results suggest that targeting p90RSK would be a good strategy to increase Cis-DDP sensitivity in triple-negative breast cancers.

Keywords

References

  1. Jung J, Jang K, Ju JM et al (2018) Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model. Cancer Lett 428, 127-138 https://doi.org/10.1016/j.canlet.2018.04.020
  2. Park J, Jang JH, Park GS, Chung Y, You HJ and Kim JH (2018) BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer. BMB Rep 51, 373-377 https://doi.org/10.5483/BMBRep.2018.51.8.127
  3. Dasari S and Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740, 364-378 https://doi.org/10.1016/j.ejphar.2014.07.025
  4. Verma N, Muller AK, Kothari C et al (2017) Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Res 77, 86-99 https://doi.org/10.1158/0008-5472.CAN-16-1797
  5. Qin H, Liu X, Li F et al (2017) PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Cancer Lett 409, 30-41 https://doi.org/10.1016/j.canlet.2017.08.019
  6. Kim HB and Myung SJ (2018) Clinical implications of the Hippo-YAP pathway in multiple cancer contexts. BMB Rep 51, 119-125 https://doi.org/10.5483/BMBRep.2018.51.3.018
  7. Ludwik KA, Campbell JP, Li M et al (2016) Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Mol Cancer Ther 15, 2598-2608 https://doi.org/10.1158/1535-7163.MCT-16-0106
  8. Lin L, White SA and Hu K (2019) Role of p90RSK in Kidney and Other Diseases. Int J Mol Sci 20, pii: E972
  9. Chen S and Mackintosh C (2009) Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes. Cell Signal 21, 1984-1993 https://doi.org/10.1016/j.cellsig.2009.09.009
  10. Ikuta M, Kornienko M, Byrne N et al (2007) Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein Sci 16, 2626-2635 https://doi.org/10.1110/ps.073123707
  11. Tas I, Han J, Park SY et al (2019) Physciosporin suppresses the proliferation, motility and tumourigenesis of colorectal cancer cells. Phytomedicine 56, 10-20 https://doi.org/10.1016/j.phymed.2018.09.219
  12. Melhuish TA, Kowalczyk I, Manukyan A et al (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861, 983-995 https://doi.org/10.1016/j.bbagrm.2018.10.005
  13. de Cassia Viu Carrara R, Fontes AM, Abraham KJ et al (2018) Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls. Clin Transl Oncol 20, 542-549 https://doi.org/10.1007/s12094-017-1751-x
  14. Lim W, Yang C, Park S, Bazer FW and Song G (2017) Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K/AKT and MAPK Signal Transduction Cascades. J Cell Physiol 232, 1428-1440 https://doi.org/10.1002/jcp.25637
  15. Zhao T, Li R, Tan X et al (2018) Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK/RhoA-Mediated mTORC1/NF-kappaB and ERK1/2 Pathways. Int J Mol Sci 19, 1994 https://doi.org/10.3390/ijms19071994
  16. Sheng W, Chen C, Dong M et al (2017) Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. Cell Death Dis 8, e3147 https://doi.org/10.1038/cddis.2017.547
  17. Kuwano M, Shibata T, Watari K and Ono M (2019) Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci 110, 1536-1543 https://doi.org/10.1111/cas.14006
  18. Moon HG, Yi JK, Kim HS et al (2012) Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer. BMC Cancer 12, 585 https://doi.org/10.1186/1471-2407-12-585
  19. Ashaie MA and Chowdhury EH (2016) Cadherins: The Superfamily Critically Involved in Breast Cancer. Curr Pharm Des 22, 616-638 https://doi.org/10.2174/138161282205160127095338
  20. Wang Y and Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30, 603-611 https://doi.org/10.5732/cjc.011.10226
  21. Hong J, Zhou J, Fu J et al (2011) Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res 71, 3980-3990 https://doi.org/10.1158/0008-5472.CAN-10-2914
  22. Lin S, Zhang C, Liu F et al (2019) Actinomycin V Inhibits Migration and Invasion via Suppressing Snail/Slug-Mediated Epithelial-Mesenchymal Transition Progression in Human Breast Cancer MDA-MB-231 Cells In Vitro. Mar Drugs 17, 305 https://doi.org/10.3390/md17050305
  23. Harquail J, LeBlanc N, Landry C, Crapoulet N and Robichaud GA (2018) Pax-5 Inhibits NF-kappaB Activity in Breast Cancer Cells Through IKKepsilon and miRNA-155 Effectors. J Mammary Gland Biol Neoplasia 23, 177-187 https://doi.org/10.1007/s10911-018-9404-4
  24. Heo KS, Chang E, Takei Y et al (2013) Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arterioscler Thromb Vasc Biol 33, 321-329 https://doi.org/10.1161/ATVBAHA.112.300619
  25. Heo KS, Le NT, Cushman HJ et al (2015) Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest 125, 1299-1310 https://doi.org/10.1172/JCI76453